We also note that durvalumab-treated patients showed a trend toward a greater increase in sPD-L1 than atezolizumab-treated patients ( Figure 4H ).
← all excerpts
Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.
1
—
—